AgenT, a life sciences company, is dedicated to combatting Alzheimer’s disease by focusing on its silent phase. The challenge lies in identifying the Alzheimer’s pattern amid countless potential signals. Employing Artificial Intelligence, the company’s multiomics platform is crafted to identify Alzheimer’s in its initial stages, aiding clinicians in optimizing the next generation of precision therapies. Through the integration of multiomics assays and advanced machine learning techniques, AgenT has identified new blood biomarkers that are deregulated from the earliest stages of the disease. Utilizing this proprietary database, the company is actively developing precise blood diagnostics and the next generation of precision therapies for the treatment of Alzheimer’s.